Pharmaceutics, Volume 12, Issue 2 (February 2020) – 110 articles
Cover Story (view full-size image): Conventional type 1 dendritic cells (cDC1) superiorly prime antigen-specific cytotoxic T cells and activate NK cells. Accordingly, multiple approaches have been tested, aiming for their use in antitumor vaccines: genetically modifying tumor cells to express the cDC1-recruiting chemokine XCL1; in vivo targeting of tumor antigens to restricted markers, such as CLEC9A or XCR1; ex vivo differentiation from hematopoietic CD34+ precursors or from induced pluripotent stem cells; and direct reprograming from fibroblasts. Although in its beginnings, the clinical exploitation of cDC1 to empower antitumor immunotherapies is a highly promising field. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.